Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:9/10/2007

ts (antigens) on the cancer cell.

2) It directly kills cancer cells.

3) It signals the immune system to mount an effective and sustainable

anti-tumor immune response by changing the type of cells that

infiltrate and attack the tumor from the 'usual' CD-8 cells to the

CD-4 cells. This is important because:

-- The tumor is able to shut down the infiltrating CD-8 cells,

but is unable to shut down the CD-4 cell attack, and

-- CD-4 cells help break 'tumor tolerance', thereby allowing

the immune system to recognize, attack, and destroy the

tumor. (The normal immune system is 'blind' to tumor cells

because the tumor cells are derived from the body's own

cells, and thus the body 'thinks' of the tumor as 'self', a

phenomenon also known as 'tumor tolerance'.)

4) Multikine has been shown to render the remaining cancer cells much

more susceptible to radiation and chemotherapy treatment, thereby

making these treatments more effective.

Our U.S. and Canadian cleared Phase III clinical trial is designed to prove that Multikine is effective in the treatment of advanced primary head and neck cancer patients. This disease is being developed as Multikine's first indication because it is a fatal disease with an unmet medical need. Over the past 50 years there has been very little improvement in the survival of these patients (about 50% after 3 years).

However, because Multikine simulates a healthy immune response, it is also expected to be effective in treating many other tumors. Multikine will be developed for use in treating breast cancer, skin cancer and cervical cancer. Studies will also be conducted to confirm observations made during Phase II clinical studies that Multikine has the ability to increase the effectiveness of radiation and chemotherapy. This may someday lead to an ability to reduce the amounts of
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
3. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
4. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
5. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
6. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
7. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
8. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
9. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
10. State of Diabetes in Pittsburgh: Pittsburgh Business Group on Health Releases Report
11. Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma Corp. ... biopharmaceutical company developing therapeutic products for rare diseases, ... the European Organisation for Rare Diseases™ (EURORDIS™), The ... in observing Rare Disease Day. On ... organizations, industry, and other participants conduct special events ...
(Date:2/27/2015)... 2015  PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the fourth quarter and full year ended ... transformative year for PTC. We are now a growing ... therapies in the rare disease space," stated Stuart W. ... are proud to bring the first treatment for Duchenne ...
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... and markets innovative proprietary products to treat voiding dysfunctions, ... Annual ROTH Conference on Tuesday, March 10, 2015. ... Reynolds , Chief Financial Officer, will present at 4:00 ... one at the conference at the Ritz Carlton in ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Uroplasty to Participate in the 27th Annual ROTH Conference 2
... COCOA, Fla., March 22, 2011 GeNO LLC ... technology company, today announced commencement of  the PHiano ... Treatment of Pulmonary Hypertension in patients with Pulmonary ... Idiopathic Pulmonary Fibrosis (PH-IPF) using Inhaled NITROSYL™ nitric ...
... MADISON, Wis., March 22, 2011 ... two-year collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) ... predictive tool for assessing the potential cardiotoxic effects of ... transitioning into a standard supply agreement.  Moving forward, iCell ...
Cached Medicine Technology:GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 2GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 3Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule 2
(Date:2/28/2015)... (PRWEB) February 28, 2015 ... of outsourced sales, marketing and supply chain management ... BIOTA Botanicals, is bringing its award winning solutions ... BIOTA Botanicals’ products are specifically created to combat ... experts, BIOTA is committed to marrying science with ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 How ... Supportive? Strategic? , There are all kinds of ... To raise awareness of the advantages and applications ... PeopleKeys is launching a new product this spring ... better understand the connection between personality type, leadership, ...
(Date:2/28/2015)... Javon Bea Mercy Health System ... as stroke capable by the State of Illinois, enabling ... Mercy Harvard Hospital. , The hospital was required to ... to treat stroke according to national standards of care ... patients to bypass hospitals not designated as an Emergent ...
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand in ... Vegas, Nevada for the annual ASD Market Week tradeshow. ... consumer-goods tradeshows and My Shiney Hiney will be one of ... Hiney can be found at booth number C1663. , My ... personal hygiene brush and cleansing system exclusively created to clean ...
(Date:2/27/2015)... 2015 A new study published in ... men who cycle on a regular basis and prostate cancer. ... suggests that the more hours per week a man spends ... leading to an increased importance on prostate cancer screening methods. ... look more closely at patents’ risk factors for developing prostate ...
Breaking Medicine News(10 mins):Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3
... of the tissue culture variety of anti-rabies vaccine, West ... the restricted nerve tissue variety vaccine till the demand-supply ... Surjyakanta Mishra told reporters here today that the Centre ... years ago citing side-effects., ,"However, since the demand-supply ...
... had affected more than 2.85 lakh population in parts of Karnataka ... , ,As against 1.20 lakh cases reported till April this ... in June so far, Minister for Health R Ashok said while ... that the government has failed to take urgent steps to contain ...
... suggests that the belief of being watched makes people behave more honestly, ... team monitored people dropping money in a canteen ... people put nearly three times more money when a poster ... poster showing flowers. , The poster might have ...
... Allison, a University of Alabama biostatistician has compiled a report ... was assisted in this venture by 19 other scientists in ... looked at more than 100 studies on the reasons for ... reasons could be an answer ,* Inadequate sleep: ...
... harassment and violence have become a way of life in ... name of combating Maoist guerrillas, say child rights activists here. ... of 36 rights organisations, says it has been urging the ... security forces from all occupied schools but to no avail. ...
... be the combination of dry eyes and mouth//, which lasts ... dry, gritty or burning eyes, intermittent blurry vision, a dry ... glands. The parotids are a pair of salivary glands behind ... and symptoms may include dry skin or vaginal dryness in ...
Cached Medicine News:Health News:Girl Students Sexually Harassed by Security Forces in Nepal 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Cottle Tenaculum Skin Hook. 5 1/2" small, shallow curve....
Goldman single hook....
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl...
Medicine Products: